← All indications
Coronary Artery Disease
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
Drugs by status
Approved for this indication (29)
- ramipril
- ammonia
- pravastatin
- amlodipine
- simvastatin
- arbutamine
- ioxaglic acid
- thallous chloride ti 201
- rubidium chloride rb-82
- isosorbide
- dipyridamole
- evolocumab
- niacin
- bempedoic acid
- atorvastatin
- ticlopidine
- malipighia punicifolia extract
- indobufen
- propranolol
- acetylsalicylic acid
- flurpiridaz
- technetium tc-99m sestamibi
- atenolol
- lovastatin
- alirocumab
- perindopril
- triparanol
- nitroglycerin
- fludeoxyglucose f-18
Phase 4 trials (182)
- polidocanol
- urea
- sorbitol
- iopromide
- perflutren protein-type a microspheres
- pioglitazone
- mebhydrolin napadisilate
- tirzepatide
- sufonylurea
- meperidine
- magnesium lactate
- zotarolimus
- alpha-lipoic acid
- inclisiran
- custodiol
- morphine
- glimepiride
- urokinase
- tirofiban
- sitagliptin
- esomeprazole
- ranibizumab
- remifentanil
- cilostazol
- nesiritide
- ezetimibe
- vorapaxar
- cholesterol
- pitavastatin
- hydroxyethyl starch
- +152 more
Phase 3 trials (71)
- l-alanyl-l-glutamine
- colestipol
- ayurvedic suved
- conjugated equine estrogens
- n(2)-l-alanine l-glutamine dipeptide
- bovine colostrum
- apadenoson
- pegnivacogin
- methotrexate
- chlorhexidine
- red blood cells
- canagliflozin
- genistein
- l-glutamine
- sulfur hexafluoride lipid-type a microspheres
- sotalol
- edifoligide
- paricalcitol
- garlic
- gadobutrol
- estrogen
- radiolabeled albumin technetium Tc-99m albumin colloid kit
- phytosterol
- edetic acid
- phentolamine mesylate
- bupivacaine
- gallium-68-dotatate
- allogeneic adipose derived mesenchymal stem cell
- perfluorobutane
- testosterone
- +41 more
Phase 2 trials (83)
- intracoronary infusion of progenitor cells
- advegfxc1
- pz-128
- mepolizumab
- darusentan
- atopaxar
- varespladib methyl ester
- hemoglobin glutamer 250
- padma 28
- autologous cd34+ cells
- orticumab
- argatroban
- wharton's jelly mesenchymal stem cells
- nicotinamide
- ketoglutarate
- cardiopet
- pmx-60056
- bfpet
- xc001
- serelaxin
- rilonacept
- pradigastat
- selected cd 133+ cells
- xtr004
- naltrexone
- sar-407899
- arginine
- imb-1018972
- resten-mp
- fgf-1
- +53 more
Phase 1 trials (29)
- acetylcholine chloride
- 68ga-bnota-prgd2
- crizotinib
- rifampin
- bms747158
- rhodamine b
- isoflurane
- N-Hydroxy-nor-L-arginine
- xtr003
- ga-68 galmydar
- human placental derived stem cells
- Filgrastim
- moxifloxacin
- bone marrow derived autologous cd34+ selected cells
- autologous skeletal myoblast
- cabazitaxel
- cocoa bean
- cardiac stem cells
- anginera
- bradykinin
- mcrci stem cells
- sar247799
- dmdpa
- vericiguat
- alteplase
- vortioxetine
- stem cells
- 123i-cmice
- sildenafil
Other trials (54)
- coconut oil
- varenicline
- ciprofloxacin
- fluconazole
- glitazone
- endothelial outgrowth cells
- ergocalciferol
- beetroot juice
- anakinra
- beta-d-adenosine
- gadoversetamide
- flax
- primaquine
- gadopenteate dimeglumine
- sulfasalazine
- melatonin
- xuebijing
- xuefu zhuyu
- hydroxytyrosol
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- curcumin
- amino acids
- ondansetron
- olanzapine
- guanxin shutong
- sargramostim
- glucagon-like peptide-1
- ellagic acid
- ferrous citrate, fe-59
- gabapentin
- +24 more
Organizations
Organization Involved with Phase 4 Indications (352)
- Denver Research Institute
- Hallym University
- University of Iowa
- Chonbuk National University
- University of Connecticut
- Loyola University
- Research Institute for Complex Problems of Cardiovascular Diseases, Russia
- University of British Columbia
- University of Adelaide
- Hospital Avicenne
- Hospital Italiano de Buenos Aires
- Kyung Hee University
- Daewoong Pharmaceutical Co. LTD.
- Duke University
- Central South University
- Terumo Corporation
- CHU Besançon
- National Heart, Lung, and Blood Institute (NHLBI)
- Queen's University, Belfast
- Southeast University
- East Carolina University
- Zhejiang University
- Imam Abdulrahman Bin Faisal University
- Maastricht University
- Kaiser Franz Josef Hospital
- Kobe University
- The Alfred Hospital
- University of Montreal
- University of California, Los Angeles
- University of Cologne
- +322 more
Organization Involved with Phase 3 Indications (152)
- University of Lille
- Yeshiva University
- University of Lausanne
- University of Groningen
- PPD
- Resverlogix Corp
- University of Las Palmas de Gran Canaria
- Cambridge Theranostics Ltd
- George Washington University
- Universidad del Norte, Barranquilla
- Assiut University
- Institute of Cardiology, Warsaw, Poland
- University of Rome Tor Vergata
- Rutgers University
- University of Hamburg
- Norwegian Heart and Lung Patient Organisation
- Solvay
- Miltenyi Biotec, Inc.
- University of Michigan
- Venezuelan Foundation of Heart Failure
- University of Saskatchewan
- University of Verona
- Steno Diabetes Center Copenhagen
- Baxalta
- Mario Negri Institute
- AbbVie
- Catharina Ziekenhuis Eindhoven
- University of Edinburgh
- Taichung Veterans General Hospital
- Genzyme
- +122 more
Organization Involved with Phase 2 Indications (119)
- Foundation for Biomedical Research and Innovation
- Canadian Anesthesiologists' Society
- German Center for Cardiovascular Research e. V. (DZHK)
- University of Nantes
- Mianyang Central Hospital
- Okayama University
- National Institutes of Health (NIH)
- Shandong University of Traditional Chinese Medicine
- Synvista Therapeutics, Inc
- Biomarin
- Guang Anmen Hospital
- Medical University of South Carolina
- University of Grenoble
- CV Therapeutics
- Heart and stoke fondation of Quebec
- St. Luke's-Roosevelt Hospital Center
- Papworth Hospital NHS Foundation Trust
- Universidad Autonoma de Madrid
- Richardson Centre for Functional Foods and Nutraceuticals
- Mercy Gilbert Medical Center
- South Australian Health and Medical Research Institute
- Fundacion Investigacion y Desarrollo
- University of South Carolina
- Covance
- InfraReDx
- Government of France
- Cell>Point LLC
- Russian Academy of Medical Sciences
- The TIMI Study Group
- Kent Hospital, Rhode Island
- +89 more
Organization Involved with Phase 1 Indications (27)
- Bioheart, Inc.
- University of Eastern Finland
- Heart Center BH Tuzla
- Lee's Pharmaceutical
- Canadian Institutes of Health Research (CIHR)
- Chang Gung University
- Masih Daneshvari Hospital
- University of Louisville
- University of California, Davis
- Aldagen
- Liuhuaqiao Hospital
- Brain & Behavior Research Foundation
- Honya Medical Inc
- St. Louis University
- McGill University
- University of Nebraska
- University of Kentucky
- Cytori Therapeutics
- AlphaCore Pharma LLC
- Healthcare Discoveries Inc.
- Yale University
- RegeneRx Biopharmaceuticals, Inc.
- Theregen, Inc.
- Baylor University
- SeaView Research
- European Commission
- Synektik S.A.
Organization Involved with Other Experimental Indications (81)
- Maine Center for Lipids and Cardiovascular Health
- Fosun
- Haemonetics Corporation
- Odessa Heart Institute
- AppliedVR, Inc.
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Saint Francis Memorial Hospital
- Chinese People's Armed Police Forces
- University of Pennsylvania
- Guangzhou University of Chinese Medicine
- St. John's Research Institute
- Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region
- Henan Institute of Cardiovascular Epidemiology
- Federal University of Rio de Janeiro
- Shantou University
- Jinan University
- NHS National Waiting Times Centre Board
- Free University of Brussels
- POM Wonderful LLC
- The Korean Society of Cardiology
- Foundation for Anesthesia Education and Research
- Sun Yat-Sen University
- Medela AG
- Beijing Municipal Health Bureau
- Utah State University
- Luzerner Kantonsspital
- Cardialysis BV
- American Egg Board
- University of Stavanger
- Ruhr University Bochum
- +51 more